Generated August 11, 2026 at 8:32 PM ET
· Covers August 11 trading day
· 10 of 306 ready 8-Ks selected
· AI-assisted overview
Today's 8-K filings featured several high-materiality events. RYTHM (RYM) removed ownership caps, allowing Green Thumb affiliate RSLGH to control approximately 89.9% of its shares. Joby Aviation (JOBY) announced a ~$500M acquisition of Resonant Sciences and launched a $750M at-the-market offering. Absci (ABSI) reported positive interim Phase 1 data for ABS-201 and completed a $100M offering. Additionally, National CineMedia (NCMI) acquired Captivate for $275M, and Apogee Therapeutics (APGE) stockholders approved the AbbVie merger.
HOTH
Hoth Therapeutics, Inc.
regulatory
negative
materiality 0.80
August 11, 2026, 4:05 PM ET
Rocket One faces Nasdaq delisting notice for low bid price; joins Seagate Partner Program
- On Aug 6, 2026, Nasdaq notified Rocket One of non-compliance with $1.00 min bid price rule; stock continues trading under RKTO.
- Company has until Feb 2, 2027 to regain compliance by closing at >=$1.00 for 10 consecutive business days; may get 180-day extension.
- Company may consider a reverse stock split to cure the deficiency; delisting risk if not cured.
M&A
positive
materiality 0.90
August 11, 2026, 8:00 AM ET
Joby Aviation to acquire Resonant Sciences for ~$500M; also launches $750M ATM
- Acquisition price ~$500M: $450M cash + $50M in Joby common stock; stock consideration fixed at signing.
- Resonant TTM revenue >$100M, up ~40% YoY; high-teens adjusted EBITDA margins; ~250 employees.
- Closing expected H1 2027, subject to regulatory/national security approvals; Resonant CEO J. Micah North to lead dedicated defense unit.
NCMI
National CineMedia, Inc.
M&A
positive
materiality 0.80
August 11, 2026, 4:10 PM ET
NCM acquires Captivate for $275M (10x EBITDA), expands to 48k screens, pauses dividend
- Acquires 100% of Captivate for $275M enterprise value (~10x pro forma EBITDA); cash consideration.
- Captivate 2025 revenue ~$64M, Adj EBITDA ~$19M; grew ~40% and >50% over past two years.
- Combined network: 48,000+ screens across 185 DMAs incl. all top 100; adds office/residential.
APGE
Apogee Therapeutics, Inc.
M&A
positive
materiality 0.80
August 11, 2026, 4:00 PM ET
Apogee stockholders approve AbbVie merger; advisory comp proposal fails
- Merger proposal approved: 46,508,107 for, 3,885 against, 14,261 abstentions, satisfying a closing condition.
- Non-binding compensation proposal failed: 19,323,605 for vs 27,123,259 against; not a condition to close.
- All seven directors (Henderson, McKenna, Bollinger, Fox, Jones, Kiselak, Shah) to resign effective at merger close.
GROV
Grove Collaborative Holdings, Inc.
regulatory
negative
materiality 0.75
August 11, 2026, 4:07 PM ET
Grove receives NYSE non-compliance notice for market cap/equity below $50M
- On Aug 7, 2026, NYSE notified Grove it failed Section 802.01B: average market cap <$50M over 30 trading days and stockholders' equity <$50M.
- Grove must submit a business plan within 45 days (by ~Sept 21, 2026) demonstrating ability to regain compliance within 9-month cure period.
- NYSE notice has no immediate impact on listing of Class A common stock; trading continues subject to other listing standards.
earnings
positive
materiality 0.90
August 11, 2026, 4:06 PM ET
Absci reports positive interim Phase 1 data for ABS-201; completes $100M offering
- Positive interim Phase 1 data for ABS-201: well tolerated, half-life ≥65 days, supports 2-3 doses/6 months.
- Completed $100M underwritten offering incl. $40M strategic investment from Eli Lilly; net proceeds $93.6M.
- Cash and securities $201.1M at 6/30/26, up from $125.7M at 3/31/26; runway into H2 2028.
earnings
negative
materiality 0.80
August 11, 2026, 5:29 PM ET
Inuvo Q2 2026: revenue down 67% to $7.5M, net loss $4.0M; CFO Ruiz to retire
- Q2 net revenue $7.5M, down 67% YoY; Audience Modeling up 19%, Legacy Search down 80%.
- Net loss $4.0M ($0.27/share) vs $1.5M loss ($0.10) in Q2 2025; adjusted EBITDA loss $1.8M.
- Raised ~$13M gross: $10.3M secured notes in Q2, $3.0M stock/warrants post-quarter; retired prior debt.
earnings
positive
materiality 0.80
August 11, 2026, 5:04 PM ET
FocalTherics reports preliminary Q2 2026 HIFU revenue $12.7-13.2M, up 34-39% YoY; ESWL held for sale
- Q2 2026 HIFU revenue $12.7M-$13.2M (+34-39% YoY); gross margin 54-56% (+3-5 pts); operating loss ($8.5M)-($7.5M).
- ESWL and Distribution segments classified as discontinued operations/held for sale; HIFU reported as continuing operations.
- Sold 13 Focal One systems (+44% YoY); installed base 184 (+38 vs Q2'25); U.S. procedure volume +47% YoY.
debt
negative
materiality 0.80
August 11, 2026, 4:36 PM ET
Synergy CHC receives default notice on $17.6M term loan; forbearance terminated
- Received default notice from ACP Agency on Aug 11, 2026 for missed interest payment due Aug 3; cure period expired Aug 6.
- Forbearance period terminated; $404,173.06 forbearance fee now due and payable.
- Approximately $17.6M principal outstanding under Credit Agreement; ACP may accelerate and charge post-default interest.
other material
negative
materiality 1.00
August 11, 2026, 7:00 AM ET
RYTHM removes ownership caps; Green Thumb affiliate RSLGH to control ~89.9% of shares
- Amendment removes 49.99% beneficial ownership limits on $72M notes and warrants covering up to 9,731,638 shares, effective Oct 10, 2026.
- RSLGH (Green Thumb) ownership rises from 49.99% to ~89.9% of RYTHM common stock as of Aug 11, 2026.
- Aggregate consideration of $109.5M funded from Green Thumb working capital, plus interest under notes and fees under services agreement.